What Is the Lowest Dose of Wegovy? Understanding the Starting Point

What Is the Lowest Dose of Wegovy? Understanding the Starting Point

By Dr. Onikepe Adegbola, MD PhD

The lowest dose of Wegovy is 0.25 mg, administered as a once-weekly subcutaneous injection. Every patient starts here. It doesn't matter if you weigh 200 pounds or 400 pounds, if you've been on other GLP-1 medications before, or if you're eager to start losing weight as quickly as possible. The 0.25 mg dose is the mandatory entry point, and it serves a specific clinical purpose that has nothing to do with weight loss.

Here's what the lowest dose of Wegovy does, why it exists, and what the path from 0.25 mg to the full dose looks like.

Why the Lowest Dose of Wegovy Exists

Semaglutide — the active ingredient in Wegovy — is a potent GLP-1 receptor agonist. It slows gastric emptying, suppresses appetite through hypothalamic signaling, reduces glucagon secretion, and alters reward-center processing of food. Introducing all of these effects at full intensity from day one would be miserable for most patients. The GI system needs time to acclimate.

The 0.25 mg starting dose is below the threshold for meaningful weight loss in most individuals. In the STEP clinical trials, the weight loss curve is nearly flat during the first month. This isn't a failure of the medication. It's an intentional design choice that reduces the severity and duration of GI side effects at higher doses.

Think of it as priming. The receptor signaling pathways are being activated gently. The gastric motility is slowing incrementally. The hypothalamic appetite centers are adjusting to a new input signal. By the time you reach the doses that produce significant appetite suppression and weight loss (1 mg and above), your body has had 8+ weeks to adapt.

What Happens at 0.25 mg Physiologically

At this lowest dose, patients may experience:

• Subtle appetite reduction: Some patients report feeling slightly less hungry. Many notice nothing.
• Mild GI effects: Occasional nausea, usually brief. Possibly some constipation or loose stools as motility patterns shift.
• Minimal weight change: Typical weight change in the first month is 0-3 pounds. Some patients gain weight initially due to fluid shifts or continued normal eating.
• Improved fasting glucose: Even at sub-therapeutic doses, some patients with insulin resistance show modest fasting glucose improvements.

The absence of dramatic effects at 0.25 mg is a source of frustration for patients who expected immediate results. I spend a lot of time in the first visit setting this expectation clearly: month one is about your gut learning to work with semaglutide. The weight loss comes later. Patience here pays off in better tolerability at higher doses.

The Full Dose Escalation From the Lowest Dose of Wegovy

Wegovy's FDA-approved escalation schedule progresses through five dose tiers:

• Month 1 (Weeks 1-4): 0.25 mg weekly
• Month 2 (Weeks 5-8): 0.5 mg weekly
• Month 3 (Weeks 9-12): 1 mg weekly
• Month 4 (Weeks 13-16): 1.7 mg weekly
• Month 5+ (Week 17 onward): 2.4 mg weekly (maintenance dose)

Each step doubles or nearly doubles the previous dose. The 4-week minimum at each level allows GLP-1 receptor desensitization to occur — a process where the body adapts to a given level of receptor activation before being exposed to more. This is the same principle used in allergy immunotherapy and many drug titration protocols.

Can the Escalation Be Modified?

Yes, but only slowed down — not sped up. Prescribers can extend the duration at any dose tier if side effects are too severe. Staying at 0.25 mg for 6 or 8 weeks instead of 4 is perfectly acceptable. Some patients need to sit at the 1 mg dose for several months before advancing to 1.7 mg. The efficacy of the ultimate maintenance dose is not diminished by a slower path to get there.

What's not recommended: skipping dose levels. Jumping from 0.25 mg to 1 mg or from 0.5 mg to 1.7 mg bypasses the acclimation process and significantly increases the risk of nausea, vomiting, and diarrhea. I've seen patients who obtained compounded semaglutide without proper medical oversight try aggressive titrations. The GI consequences are predictable and unpleasant.

Staying at a Lower Dose: Is That an Option?

Some patients ask whether they can remain at a lower dose (0.5 mg or 1 mg) rather than escalating to the full 2.4 mg. The answer is nuanced.

Some patients achieve satisfactory weight loss at sub-maximum doses. If you're at 1.7 mg and losing weight consistently with minimal side effects, your prescriber may decide to stay there rather than push to 2.4 mg. The clinical trials studied the 2.4 mg dose most rigorously, so that's where the strongest evidence sits, but clinical practice allows for individualization.

Remaining at the lowest dose of Wegovy (0.25 mg) as a maintenance strategy is not supported by clinical data. This dose was not designed for therapeutic effect. If weight loss is the goal, escalation to at least 1 mg is almost always necessary, with most patients benefiting from reaching 1.7 mg or 2.4 mg.

Making the Most of the Starting Phase

The 0.25 mg phase is an opportunity, not dead time. Patients who use these first weeks strategically set themselves up for better outcomes later:

• Establish protein habits. Start tracking and building your protein intake now. When appetite drops significantly at higher doses, you'll need muscle-sparing habits already in place. Aim for 60-80g of protein daily as a minimum.
• Hydrate intentionally. Semaglutide-related constipation becomes more pronounced at higher doses. Building a hydration habit at 0.25 mg means you're already ahead when motility slows further.
• Begin nutritional supplementation. Micronutrient intake drops when food intake drops. Starting Casa de Sante GLP-1 supplements during the initiation phase means you're nutritionally supported before deficiencies develop. The low FODMAP formulations are specifically designed for the GI sensitivity that accompanies GLP-1 therapy.
• Set realistic expectations. The scale may not move much at 0.25 mg. That doesn't mean the medication isn't working. Metabolic improvements begin at the cellular level before they manifest as weight change.

What If the Lowest Dose of Wegovy Causes Significant Side Effects?

For a small percentage of patients, even the 0.25 mg starting dose triggers problematic GI symptoms — persistent nausea, vomiting, or diarrhea that interferes with daily life. This doesn't necessarily mean you can't take Wegovy. It means your GI tract is particularly sensitive to GLP-1 receptor activation, and the approach needs to be adjusted.

Options your prescriber might consider:

• Extending the 0.25 mg phase. Instead of 4 weeks, stay at the lowest dose for 6-8 weeks to give your body more time to adapt. This is the most common modification.
• Adding GI support. Antiemetics (like ondansetron) for nausea. Digestive enzymes to support motility. Probiotics to help stabilize the gut microbiome during the adjustment period. I use Casa de Sante GLP-1 supplements routinely for this — the digestive enzyme companion and synbiotic formulations are specifically designed for the GI sensitivity window during dose initiation.
• Dietary modifications. Smaller, more frequent meals. Avoiding high-fat foods that compound the slowed gastric emptying. Staying away from carbonated drinks and very spicy foods. These sound simple but make a measurable difference for many patients.
• Reassessment. In rare cases, if a patient cannot tolerate even the lowest dose of Wegovy after an extended trial with maximal support, the medication may not be the right fit. Other GLP-1 agonists or weight management approaches may be more appropriate.

The key message: experiencing side effects at the starting dose is not a reason to give up immediately. It's a reason to work with your prescriber on a modified approach. Most patients who struggle initially go on to tolerate higher doses successfully with the right support and pacing.

Frequently Asked Questions

Is 0.25 mg of Wegovy effective for weight loss?

Not meaningfully. The 0.25 mg dose is an initiation dose designed to minimize GI side effects during the acclimation period. Most patients see little to no weight loss at this dose. Significant appetite suppression and weight loss typically begin at 1 mg and become most pronounced at 1.7-2.4 mg.

How long do I stay on the lowest dose of Wegovy?

The standard protocol is 4 weeks. Your prescriber may extend this if you experience significant GI side effects that need more time to resolve. Extending the initiation phase does not compromise the medication's long-term effectiveness.

Can I start Wegovy at a dose higher than 0.25 mg?

No. The FDA-approved protocol requires all patients to start at 0.25 mg. Even patients switching from other GLP-1 agonists typically begin at the lowest Wegovy dose, though your prescriber may adjust the pace of escalation based on your prior GLP-1 experience and tolerance.

What's the difference between the lowest dose of Wegovy and the lowest dose of Ozempic?

Both start at 0.25 mg weekly, as both contain semaglutide. The difference is in the full dose range: Ozempic's maximum is 2 mg (for type 2 diabetes), while Wegovy goes up to 2.4 mg (for weight management). The initial experience at 0.25 mg is essentially identical between the two products.

Will I feel anything at the 0.25 mg dose?

Responses vary. Some patients notice mild appetite reduction or occasional nausea. Many patients feel nothing at all at this dose, which is normal and expected. The perceptible effects of semaglutide become more apparent as the dose increases through the escalation schedule.